



Luxembourg, 20 December 2024

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	PRIOTHERA (EGF VD)
Project Number:	2021-0189
Country:	Ireland
Project Description:	Priothera is a clinical stage company developing receptor modulators for haematologic malignancies, i.e. cancers that affect blood, bone marrow, and lymph nodes (e.g. Leukaemia). Priothera is developing a novel drug, mocravimod for acute myeloid leukaemia (AML) with an aim of enhancing the curative potential of Hematopoietic Stem Cell Transplantation (HSCT).

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The project mainly covered investments in RDI that were carried out in the Promoter's existing facilities or other research centres already authorised.

The promoter's R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, The Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials which are sponsored by the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

No significant environmental or social issues were noted.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.